**Preface XIII**

### **Part 1 Modeling, Methods and Technique 1**


Contents VII

Chapter 20 **Hemodialysis Vascular Access Dysfunction 365**

Chapter 21 **Nontraditional Anti - Infectious Agents in Hemodialysis 389**

Chapter 22 **Sleep in Patients with ESRD Undergoing Hemodialysis 407** 

Susanne Heiwe, Andrej Ekholm and Ingela Fehrman-Ekholm

Timmy Lee

Martin Sedlacek

Mukadder Mollaoğlu

Chapter 23 **The Importance of Exercise Programs in Haemodialysis Patients 429**


### **Part 2 Prognosis 253**

	- **Part 3 Complications 313**

Chapter 20 **Hemodialysis Vascular Access Dysfunction 365**  Timmy Lee

VI Contents

Chapter 9 **Leukocyte Function in High-Flux Hemodialysis 175** 

Jenny Olsson

Chapter 10 **Dialysis Membrane Manipulation**

Stephan Thijssen

**Part 2 Prognosis 253** 

**for Endotoxin Removal 197**  Michael Henrie, Cheryl Ford, Eric Stroup and Chih-Hu Ho

Chapter 11 **Citrate Anticoagulation in Hemodialysis 217**

Chapter 12 **Hemodialysis Principles and Controversies 227** Parin Makadia, Payam Benson, Filberto Kelly and Joshua Kaplan

Chapter 13 **Residual Renal Function in Hemodialysis Patients 255** Zachary Z. Brener, Stephan Thijssen, Peter Kotanko,

James F. Winchester and Michael Bergman

**The Linkage Between Inflammation,** 

Chapter 15 **Determinants of Cardiovascular Risk in Hemodialysis**

**Ventricular Dysfunction and Overhydration 265**

**Patients Without Significant Comorbidities 281** 

**Epidemiology in Hemodialysis Patients 297** 

**of Hyperphosphatemia in Dialysis 315** 

Hisami Yamanaka-Okumura and Yutaka Taketani

**in Chronic Renal Insufficiency: Review 349**  Oliver Rácz, Rudolf Gaško and Eleonóra Klímová

**Hyperparathyroidism in Hemodialysis Patients 331**

Rodney G. Bowden, Neil A. Schwarz and Brian D. Shelmadine

Chapter 14 **Biomarkers in Chronic Kidney Disease -** 

Chapter 16 **Malnutrition, Inflammation and Reverse**

Olimpia Ortega

Aysegul Zumrutdal

**Part 3 Complications 313** 

Chapter 18 **Management of Secondary** 

Chapter 17 **Complications and Managements** 

Eiji Takeda, Hironori Yamamoto,

Emanuel Zitt and Ulrich Neyer

Chapter 19 **Lipid and Lipoprotein Abnormalities** 


Preface

clinical field.

This book consists of three parts:

 prognosis complications

compatible devices.

modeling, methods and technique

three deal with procedures or controversies.

predict cardiovascular complications.

Hemodialysis (HD) represents the first successful long term substitutive therapy with an artificial organ for severe failure of a vital organ. Because HD was started many

Indeed, HD covers many basic and clinical aspects and this book reflects the rapid expansion of new and controversial aspects either in the biotechnological or in the

The related topics are multiple because HD includes either biotechnology or multiorgan involvement as well as different pathogenetic factors. Many efforts to reduce dialysis complications and their treatment are made. This book revises new technologies and therapeutic options to improve dialysis treatment of uremic patients.

The first part includes twelve chapters, five on modeling, water and electrolyte preparation or regulation, four face membranes and biocompatibility, the remaining

Besides important progress in biotechnology, a common and principal aim crossing most of these chapters is the attempt to reduce morbidity by the use of more

Prediction of morbidity or mortality by progress in the laboratory is a principal general topic or aim of the second group of four chapters. These chapters underline the relevance of the residual renal function and of the main laboratory biomarkers to

The third part includes seven chapters on clinical complications. The principal topic crossing two chapters is the importance of metabolic disorders for the origin and the development of the most important clinical complications (cardiovascular and bone).

decades ago, a book on HD may not appear up-to-date.
